Spirometry results after treatment for pulmonary tuberculosis: comparison between patients with and without previous lung disease: a multicenter study.


Journal

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
ISSN: 1806-3756
Titre abrégé: J Bras Pneumol
Pays: Brazil
ID NLM: 101222274

Informations de publication

Date de publication:
Historique:
received: 24 06 2018
accepted: 20 04 2019
entrez: 5 3 2020
pubmed: 5 3 2020
medline: 11 8 2020
Statut: epublish

Résumé

To compare patients with and without previous lung disease, in terms of the spirometry results after they had been treated for pulmonary tuberculosis (PTB) and cured, as well as to analyze risk factors related to functional severity. This was a cross-sectional, multicenter study conducted at four referral centers in Brazil. Patients were divided into two groups: those with a history of lung disease or smoking (LDS+ group); and those with no such history (LDS- group). Patients underwent spirometry (at least six months after being cured). Sociodemographic and clinical data were collected. A total of 378 patients were included: 174 (46.1%) in the LDS+ group and 204 (53.9%) in the LDS- group. In the sample as a whole, 238 patients (62.7%) had spirometric changes. In the LDS+ group, there was a predominance of obstructive lung disease (in 33.3%), whereas restrictive lung disease predominated in the LDS- group (in 24.7%). Radiological changes were less common in the LDS- group than in the LDS+ group (p < 0.01), as were functional changes (p < 0.05). However, of the 140 (79.1%) LDS- group patients with a normal or minimally altered chest X-ray, 76 (54%) had functional changes (p < 0.01). The risk factors associated with functional severity in the LDS- group were degree of dyspnea (p = 0.03) and moderate or severe radiological changes (p = 0.01). Impaired pulmonary function is common after treatment for PTB, regardless of the history of lung disease or smoking. Spirometry should be suggested for patients who develop moderate/severe dyspnea or relevant radiological changes after treatment for PTB.

Identifiants

pubmed: 32130330
pii: S1806-37132020000200206
doi: 10.36416/1806-3756/e20180198
pmc: PMC7462712
pii:
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng por

Sous-ensembles de citation

IM

Pagination

e20180198

Références

Eur Respir J. 2007 Dec;30(6):1180-5
pubmed: 17804445
Am J Psychiatry. 1974 Oct;131(10):1121-3
pubmed: 4416585
J Bras Pneumol. 2006 Jan-Feb;32(1):43-7
pubmed: 17273568
Eur Respir J. 2015 Oct;46(4):1104-12
pubmed: 26113680
Clin Respir J. 2017 May;11(3):285-295
pubmed: 28268242
Am Rev Respir Dis. 1983 Jun;127(6):725-34
pubmed: 6859656
Int J Chron Obstruct Pulmon Dis. 2016 Jun 16;11:1307-16
pubmed: 27366058
BMC Pulm Med. 2016 Apr 23;16(1):58
pubmed: 27107713
Int J Infect Dis. 2015 Mar;32:138-46
pubmed: 25809770
Rev Saude Publica. 1986 Feb;20(1):21-5
pubmed: 3749773
Respiration. 2013;86(1):76-85
pubmed: 23652030
BMC Public Health. 2010 May 19;10:259
pubmed: 20482835
Ann Intern Med. 1997 Dec 15;127(12):1072-9
pubmed: 9412309
Int J Tuberc Lung Dis. 2015 Jul;19(7):808-10
pubmed: 26056106
Chest. 2008 Feb;133(2):343-9
pubmed: 17951621
Braz J Infect Dis. 2015 Sep-Oct;19(5):492-7
pubmed: 26254689
PLoS One. 2012;7(5):e37978
pubmed: 22662259
Turk Thorac J. 2017 Apr;18(2):57-64
pubmed: 29404162
Int J Tuberc Lung Dis. 2009 Dec;13(12):1500-6
pubmed: 19919767
Thorax. 2006 Mar;61(3):259-66
pubmed: 16227332
Int J Tuberc Lung Dis. 2015 May;19(5):589-95
pubmed: 25868029
J Bras Pneumol. 2017 Jan-Feb;43(1):38-43
pubmed: 28380187
MMWR Morb Mortal Wkly Rep. 2009 Nov 13;58(44):1227-32
pubmed: 19910909
Arch Bronconeumol. 2003 Apr;39(4):146-52
pubmed: 12716554
PLoS One. 2015 Apr 27;10(4):e0125020
pubmed: 25915938
Rev Port Pneumol. 2011 Sep-Oct;17(5):216-21
pubmed: 21803536
Rev Assoc Med Bras (1992). 2008 Sep-Oct;54(5):406-10
pubmed: 18989560
Int J Tuberc Lung Dis. 2013 Jun;17(6):810-3
pubmed: 23676167
J Bras Pneumol. 2007 Jul-Aug;33(4):397-406
pubmed: 17982531
S Afr Med J. 2017 Apr 25;107(5):440-445
pubmed: 28492127
J Bras Pneumol. 2016 Sep-Oct;42(5):374-385
pubmed: 27812638
Clinics (Sao Paulo). 2011;66(4):549-56
pubmed: 21655745

Auteurs

Eliane Viana Mancuzo (EV)

. Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil.
. Laboratório de Função Pulmonar, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil.

Eduardo Martins Netto (E)

. Programa de Pós-Graduação em Medicina e Saúde, Universidade Federal da Bahia, Salvador (BA) Brasil.
. Instituto Brasileiro para a Investigação da Tuberculose - IBIT - Fundação José Silveira, Salvador (BA) Brasil.

Nara Sulmonett (N)

. Laboratório de Função Pulmonar, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil.

Vanessa de Souza Viana (VS)

. Grupo de Pesquisas em Micobacterioses, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil.

Júlio Croda (J)

. Faculdade de Ciências da Saúde, Universidade Federal da Grande Dourados, Campo Grande (MS) Brasil.

Afranio Lineu Kritski (AL)

. Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro (RJ) Brasil.
. Rede Brasileira de Pesquisa em Tuberculose - Rede TB - Rio de Janeiro (RJ) Brasil.

Fernanda Carvalho de Queiroz Mello (FCQ)

. Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro (RJ) Brasil.
. Instituto de Doenças do Tórax, Universidade Federal do Rio de Janeiro, Rio de Janeiro (RJ) Brasil.

Simone de Souza Elias Nihues (SSE)

. Curso de Fisioterapia, Centro Universitário da Grande Dourados, Dourados (MS) Brasil.

Karen Rosas Sodre Azevedo (KRS)

. Laboratório de Fisiopatologia Pulmonar, Instituto de Doenças do Tórax, Universidade Federal do Rio de Janeiro, Rio de Janeiro (RJ) Brasil.

Silvana Spíndola de Miranda (SS)

. Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil.
. Rede Brasileira de Pesquisa em Tuberculose - Rede TB - Rio de Janeiro (RJ) Brasil.
. Ambulatório de Tuberculose e Laboratório de Pesquisa em Micobactérias, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH